PriceTargets.com logo

NASDAQ:MNKD - MannKind Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.20
  • Forecasted Upside: 33.33 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.65 As of 09/28/2021 12:33 PM ET
▼ -0.15 (-3.13%)

This chart shows the closing price for MNKD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MannKind Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MNKD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNKD

Analyst Price Target is $6.20
▲ +33.33% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for MannKind in the last 3 months. The average price target is $6.20, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 33.33% upside from the last price of $4.65.

This chart shows the closing price for MNKD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in MannKind. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/23/2021HC WainwrightReiterated RatingBuy$6.00High
5/13/2021Royal Bank of CanadaInitiated CoverageSector Perform$5.00High
3/5/2021SVB LeerinkBoost Price TargetOutperform$3.00 ➝ $5.00High
2/26/2021HC WainwrightBoost Price Target$2.50 ➝ $6.50Low
2/24/2021BTIG ResearchBoost Price TargetBuy$4.00 ➝ $8.00High
2/17/2021OppenheimerReiterated RatingBuy$7.00Low
12/29/2020BTIG ResearchReiterated RatingBuy$4.00N/A
11/5/2020Cantor FitzgeraldReiterated RatingOverweightHigh
7/14/2020OppenheimerReiterated RatingBuy$2.50Medium
6/17/2020BTIG ResearchReiterated RatingBuy$4.00High
5/28/2020OppenheimerInitiated CoverageBuy$2.50Medium
5/14/2020HC WainwrightReiterated RatingBuy$2.50High
2/26/2020HC WainwrightReiterated RatingBuy$2.50Medium
1/2/2020SVB LeerinkReiterated RatingOutperformHigh
12/23/2019OppenheimerInitiated CoverageOutperform$2.50N/A
11/7/2019HC WainwrightReiterated RatingBuy$2.50High
10/24/2019Cantor FitzgeraldInitiated CoverageOverweight$3.00High
5/14/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$3.00 ➝ $3.00High
5/8/2019HC WainwrightLower Price TargetBuy$4.00 ➝ $3.00High
3/4/2019SVB LeerinkInitiated CoverageOutperform$3.00Medium
2/22/2019SVB LeerinkInitiated CoverageOutperform$3.00High
9/25/2018HC WainwrightSet Price TargetBuy$4.00Medium
9/5/2018HC WainwrightSet Price TargetBuy$4.00High
8/3/2018HC WainwrightSet Price TargetBuy$4.00High
6/15/2018Maxim GroupReiterated RatingSellLow
6/7/2018HC WainwrightSet Price TargetBuy$5.00High
5/10/2018HC WainwrightSet Price TargetBuy$5.00High
2/28/2018Maxim GroupDowngradeHold ➝ Sell$1.00High
1/30/2018Maxim GroupReiterated RatingHoldMedium
1/25/2018S&P Equity ResearchLower Price Target$3.49 ➝ $2.77High
11/8/2017HC WainwrightReiterated RatingBuyN/A
11/1/2017Maxim GroupReiterated RatingBuy ➝ HoldN/A
10/24/2017HC WainwrightReiterated RatingBuyN/A
10/10/2017HC WainwrightInitiated CoverageBuy ➝ BuyN/A
9/1/2017Maxim GroupReiterated RatingBuyHigh
5/22/2017JPMorgan Chase & Co.Reiterated RatingUnderweightHigh
5/11/2017JPMorgan Chase & Co.Reiterated RatingSellMedium
5/11/2017Piper Jaffray CompaniesSet Price TargetSell$1.00Medium
5/8/2017S&P Equity ResearchLower Price Target$1.04 ➝ $0.83High
2/28/2017Piper Jaffray CompaniesReiterated RatingUnderweightN/A
11/11/2016JPMorgan Chase & Co.Reiterated RatingUnderweightN/A
(Data available from 9/28/2016 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2021
  • 4 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/29/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2021

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

MannKind logo
MannKind Corp. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More

Today's Range

Now: $4.65
Low: $4.64
High: $4.78

50 Day Range

MA: $4.44
Low: $3.89
High: $4.91

52 Week Range

Now: $4.65
Low: $1.78
High: $6.25

Volume

25,647 shs

Average Volume

4,174,001 shs

Market Capitalization

$1.16 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.97

Frequently Asked Questions

What sell-side analysts currently cover shares of MannKind?

The following equities research analysts have issued reports on MannKind in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, Oppenheimer Holdings Inc., Royal Bank of Canada, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for MNKD.

What is the current price target for MannKind?

5 Wall Street analysts have set twelve-month price targets for MannKind in the last year. Their average twelve-month price target is $6.20, suggesting a possible upside of 33.3%. BTIG Research has the highest price target set, predicting MNKD will reach $8.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $5.00 for MannKind in the next year.
View the latest price targets for MNKD.

What is the current consensus analyst rating for MannKind?

MannKind currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MNKD will outperform the market and that investors should add to their positions of MannKind.
View the latest ratings for MNKD.

How do I contact MannKind's investor relations team?

MannKind's physical mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company's listed phone number is (818) 661-5000 and its investor relations email address is [email protected] The official website for MannKind is www.mannkindcorp.com.